Literature DB >> 1279225

Diagnostic methods in the detection of prostate cancer: a study of a randomly selected population of 2,400 men.

O Gustafsson1, U Norming, L E Almgård, A Fredriksson, G Gustavsson, B Harvig, C R Nyman.   

Abstract

We investigated the value of digital rectal examination, transrectal ultrasonography and prostatic specific antigen (PSA) analysis as aids in general clinical practice and in the early detection of prostate cancer. Of a randomly selected population of 2,400 men 55 to 70 years old who were offered examination with digital rectal examination, transrectal ultrasound and PSA analysis, 1,782 (74%) accepted and prostate cancer was detected in 65 (3.6%). When the transrectal ultrasound results were also considered the detection rate of digital rectal examination (2.3%) was increased by 50% and the number of stage T2A or less tumors was doubled. At reexamination due to markedly high PSA values (7 micrograms/l. or more) only a few additional cancers (5%) were detected. However, it is noteworthy that 80% of the detected cancers were found among the subgroup with abnormal PSA values (4 micrograms/l. or more) and comprising 17% of the study population, which suggests the possibility of selecting a risk group at mass screening. Moreover, the positive predictive value increased from 4% (when only digital rectal examination was positive) to 71% for the combination of positive digital rectal examination, positive transrectal ultrasound and an increased PSA concentration (that is 7 micrograms/l. or greater).

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1279225     DOI: 10.1016/s0022-5347(17)37041-6

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  13 in total

1.  Prostate mechanical imaging: a new method for prostate assessment.

Authors:  Robert E Weiss; Vladimir Egorov; Suren Ayrapetyan; Noune Sarvazyan; Armen Sarvazyan
Journal:  Urology       Date:  2008-03       Impact factor: 2.649

Review 2.  Prostate cancer, screening, and prostate-specific antigen: promise or peril?

Authors:  J D Voss
Journal:  J Gen Intern Med       Date:  1994-08       Impact factor: 5.128

Review 3.  Clinical and economic considerations in the treatment of prostate cancer.

Authors:  E Varenhorst; P Carlsson; K Pedersen
Journal:  Pharmacoeconomics       Date:  1994-08       Impact factor: 4.981

4.  Transrectal ultrasound guided biopsy for detecting prostate cancer: can random biopsies be reduced using the 4-dimensional technique?

Authors:  Fawzi T Abul; Narayanaswamy Arun; Mona A Abu-Assi; Akram M Asbeutah
Journal:  Int Urol Nephrol       Date:  2007-02-17       Impact factor: 2.370

5.  Pilot study of the practical relevance of a one-step test for prostate-specific antigen in capillary blood to improve the acceptance rate in the early detection program of prostate carcinoma.

Authors:  W Berg; C Linder; G Eschholz; J Schubert
Journal:  Int Urol Nephrol       Date:  2001       Impact factor: 2.370

6.  The efficiency of the serum prostate specific antigen levels in diagnosing prostatic enlargements.

Authors:  Ingle Sp; Ingle Ramona
Journal:  J Clin Diagn Res       Date:  2012-11-10

7.  Prostate-specific antigen density--a reliable parameter for the detection of prostate cancer?

Authors:  W F Thon; F Gadban; M C Truss; M Kuczyk; U Hartmann; U Jonas
Journal:  World J Urol       Date:  1996       Impact factor: 4.226

8.  Multiple transrectal ultrasound-guided biopsies for the detection of prostate cancer and determination of tumor volume, grade, and seminal vesicle invasion.

Authors:  M Norberg; L Holmberg; C Busch; M Häggman; L Egevad; A Magnusson
Journal:  Eur Radiol       Date:  1996       Impact factor: 5.315

Review 9.  Screening for prostate cancer.

Authors:  M L Cher; P R Carroll
Journal:  West J Med       Date:  1995-03

10.  Screening for Prostate Cancer by Digital Rectal Examination and PSA Determination in Senegal.

Authors:  Lamine Niang; Charles N Kouka; Mohamed Jalloh; Sérigne M Gueye
Journal:  ISRN Oncol       Date:  2011-07-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.